• National French effort to identify actionable targets in 10,000 patients with NSCLC in order to personalize therapy
• Tumor profiling for 6 biomarkers identified a target in 46% of samples and contributed to clinical decision-making in 57% of cases

This impressive countrywide effort to define genomic alterations in a NSCLC population base provides a likely snapshot of future lung cancer oncology practice while also demonstrating that molecular assessment (and its results) can be obtained in time to affect clinical decision-making. Related to the actual findings, the frequency of alterations documented in this study was similar to what has been reported by other groups, including the Lung Cancer Mutation Consortium. KRAS remains the most common driver mutation, further heightening the need to find an effective targeted therapy for this important subset of patients.